Digital Content 
NEWS #PharmaBuzz
19 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/19/3029027/0/en/Vivoryon-Therapeutics-N-V-Shares-Highlights-from-Virtual-R-D-Update-with-KOL-Speakers.html
08 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/09/2993442/0/en/Vivoryon-Therapeutics-N-V-Presents-Topline-Phase-2-Data-from-VIVA-MIND-Strongly-Supporting-Varoglutamstat-s-Potential-to-Improve-Kidney-Function.html
11 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/11/2962052/0/en/Vivoryon-Therapeutics-N-V-Announces-Late-breaking-Oral-Presentation-at-the-American-Society-of-Nephrology-Kidney-Week-2024.html
18 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/18/2915011/0/en/Vivoryon-Therapeutics-N-V-Announces-New-Data-Showing-Unique-Treatment-Effects-of-Varoglutamstat-on-Kidney-Function-in-Patients-with-Diabetes-and-Outlines-Proposed-Clinical-Developm.html
24 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/24/2868266/0/en/Vivoryon-Therapeutics-N-V-Reports-Full-Year-2023-Financial-Results-and-Provides-Varoglutamstat-and-Strategic-Updates.html
04 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/04/2839216/0/en/Vivoryon-Therapeutics-N-V-Provides-Update-on-VIVIAD-Phase-2b-Study-of-Varoglutamstat-in-Early-Alzheimer-s-Disease.html
Share 